Glucagon‐like peptide‐1 receptor expression on human eosinophils and its regulation of eosinophil activation
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Summary: Background: Glucagon‐like peptide‐1 (GLP‐1) and its receptor are part of the incretin family of hormones that regulate glucose metabolism. GLP‐1 also has immune modulatory roles. Objectives: To measure the expression of the GLP‐1 receptor (GLP‐1R) on eosinophils and neutrophils in normal and asthmatic subjects and evaluate effects of a GLP‐1 analog on eosinophil function. Methods: Peripheral blood samples were taken from 10 normal and 10 allergic asthmatic subjects. GLP‐1R expression was measured on eosinophils and neutrophils. Subsequently, the asthmatic subjects underwent allergen and diluent inhalation challenges, and GLP‐1R expression was measured. Purified eosinophils, collected from mild asthmatic subjects, were stimulated with lipopolysaccharide (LPS) and a GLP‐1 analog to evaluate eosinophil cell activation markers CD 11b and CD 69 and cytokine (IL‐4, IL‐5, IL‐8 and IL‐13) production. Results: Glucagon‐like peptide‐1 receptor is expressed on human eosinophils and neutrophils. Eosinophil, but not neutrophil, expression of GLP‐1R is significantly higher in normal controls compared to allergic asthmatics. The expression of GLP‐1R did not change on either eosinophils or neutrophils following allergen challenge. A GLP‐1 analog significantly decreased the expression of eosinophil‐surface activation markers following LPS stimulation and decreased eosinophil production of IL‐4, IL‐8 and IL‐13, but not IL‐5. Conclusion and Clinical Relevance: Glucagon‐like peptide‐1 receptor is expressed on human eosinophils and neutrophils. A GLP‐1 analog attenuates LPS‐stimulated eosinophil activation. GLP‐1 agonists may have additional adjunctive indications in treating persons with concomitant type 2 diabetes mellitus and asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“increasing the sensation of satiety (6, 7).”
BackgroundThe role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · cited 1×
“It is an incretin hormone (4-6), which exerts its effect by stimulating glucose-dependent insulin release from pancreatic β-islet cells and”
BackgroundArakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · cited 2×
“Lipopolysaccharide (LPS)induced macrophage activation in vitro and TNF-α expression was significantly reduced following treatment with the GLP-1 analog through inhibition of the PKA/NF-κB signaling pathway (22).”
BackgroundMethodExenatide Exerts a Potent Antiinflammatory Effect
Chaudhuri, A., Ghanim, H., Vora, M., Sia, C. L., Korzeniewski, K., Dhindsa, S., Makdissi, A., & Dandona, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1508 · Cited by 284
Hogan, A. E., Gaoatswe, G., Lynch, L., Corrigan, M. A., Woods, C., O’Connell, J., & O’Shea, D. (2014) · Diabetologia · doi:10.1007/s00125-013-3145-0 · Cited by 239
Hogan, A. E., Tobin, A. M., Ahern, T., Corrigan, M. A., Gaoatswe, G., Jackson, R., O’Reilly, V., Lynch, L., Doherty, D. G., Moynagh, P. N., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2232-3 · Cited by 191
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Koliaki, C., & Doupis, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0002-3 · Cited by 140 · cited 1×
“increasing the sensation of satiety (6, 7).”
Zhu, T., Wu, X.-L., Zhang, W., & Xiao, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160920195 · Cited by 106
Calsolaro, V., & Edison, P. (2015) · CNS Drugs · doi:10.1007/s40263-015-0301-8 · Cited by 93 · cited 1×
“It is an incretin hormone (4-6), which exerts its effect by stimulating glucose-dependent insulin release from pancreatic β-islet cells and”
BackgroundTreatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38
Cited by
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
Worthington, J. J., Reimann, F., & Gribble, F. M. (2018) · Mucosal Immunology · doi:10.1038/mi.2017.73 · Cited by 262
GLP-1 receptor agonist as a modulator of innate immunity
Chen, J., Mei, A., Wei, Y., Li, C., Qian, H., Min, X., Yang, H., Dong, L., Rao, X., & Zhong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997578 · Cited by 120
GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
Abdalqadir, N., & Adeli, K. (2022) · Microorganisms · doi:10.3390/microorganisms10102061 · Cited by 119
Metadata
- Authors
- Mitchell, P. D., Salter, B. M., Oliveria, J. P., El‐Gammal, A., Tworek, D., Smith, S. G., Sehmi, R., Gauvreau, G. M., Butler, M., & O'Byrne, P. M.
- Venue
- Clinical & Experimental Allergy
- Publisher
- Wiley
- Published
- 2017-01-28
- Volume
- 47
- Issue
- 3
- Pages
- 331-338
- ISSN
- 0954-7894 (ISSN-L)
- 1365-2222
- OpenAlex
- W2560130766
- Cited by
- 78
- References
- 10
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.